You are viewing a free preview of this lesson.
Subscribe to unlock all 10 lessons in this course and every other course on LearningBro.
Vaccination is one of the most important public health measures in history, preventing millions of deaths each year. This lesson covers the principles of vaccination, types of vaccine, herd immunity, and the ethical considerations surrounding vaccination programmes, as required by the Edexcel A-Level Biology (9BI0) specification.
A vaccine is a preparation containing antigens from a pathogen (or a modified form of the pathogen) that stimulates an active immune response without causing the disease.
Exam Tip: The key to vaccination is the production of memory cells. The vaccine does not cure disease — it prepares the immune system for future encounters with the pathogen.
| Type | Description | Advantages | Disadvantages | Example |
|---|---|---|---|---|
| Live attenuated | Contains a weakened (attenuated) form of the pathogen that can replicate but not cause disease | Strong, long-lasting immunity; often needs only 1–2 doses; stimulates both humoral and cell-mediated response | Small risk of reversion to virulent form; cannot be given to immunocompromised individuals | MMR (measles, mumps, rubella); BCG (TB); oral polio (Sabin) |
| Inactivated (killed) | Contains whole pathogens that have been killed by heat, chemicals, or radiation | Safer than live vaccines; no risk of reversion | Weaker immune response; requires boosters; mainly stimulates humoral response | Inactivated polio (Salk); influenza (some formulations); hepatitis A |
| Subunit / recombinant | Contains only specific antigenic proteins from the pathogen (not the whole organism) | Very safe; no live or killed pathogen; reduced side effects | Weaker response; requires boosters and adjuvants | Hepatitis B (HBsAg protein); HPV vaccine |
| Toxoid | Contains an inactivated toxin (toxoid) produced by the pathogen | Targets the toxin, which is the cause of symptoms | Requires boosters | Tetanus; diphtheria |
| mRNA | Contains mRNA encoding a pathogen protein; the body's cells use it to make the antigen | Rapid development; no live pathogen; strong immune response | Requires cold-chain storage; newer technology | COVID-19 (Pfizer-BioNTech, Moderna) |
An adjuvant is a substance added to a vaccine to enhance the immune response.
| Adjuvant | How it works |
|---|---|
| Aluminium salts (alum) | Slow the release of antigen at the injection site; attract and activate immune cells |
| Oil-in-water emulsions | Enhance antigen uptake by APCs |
Adjuvants increase the effectiveness of vaccines, particularly subunit and inactivated vaccines, which on their own produce a relatively weak immune response.
Booster doses are additional doses given after the initial vaccination course. They are necessary when:
Herd immunity (or community immunity) occurs when a sufficiently high proportion of a population is immune to a disease, reducing its ability to spread and indirectly protecting those who are not immune.
The proportion of the population that must be immune to prevent sustained transmission depends on the basic reproduction number (R₀) of the disease.
Herd immunity threshold = 1 − (1/R₀)
| Disease | R₀ | Herd immunity threshold |
|---|---|---|
| Measles | 12–18 | ~92–95% |
| Diphtheria | 6–7 | ~83–85% |
| Influenza | 1.5–2 | ~33–50% |
| COVID-19 (original) | 2–3 | ~50–67% |
| Polio | 5–7 | ~80–86% |
Exam Tip: Measles has a very high R₀, meaning a very high vaccination rate (>95%) is needed for herd immunity. When vaccination rates drop below this threshold, outbreaks occur — as seen in recent measles outbreaks in communities with low vaccine uptake.
| Term | Definition | Example |
|---|---|---|
| Eradication | Complete and permanent worldwide removal of a disease | Smallpox (eradicated in 1980 by WHO vaccination campaign) |
| Elimination | Reduction of disease incidence to zero in a defined geographical area | Polio — eliminated from most countries; close to global eradication |
Some pathogens can change their surface antigens over time, making it difficult for the immune system (and vaccines) to recognise them.
| Type | Description | Example |
|---|---|---|
| Antigenic drift | Small, gradual mutations in surface antigen genes (e.g. haemagglutinin and neuraminidase in influenza) | Seasonal flu — requires annual vaccine reformulation |
| Antigenic shift | Major change in surface antigens, often due to reassortment of genetic segments between different strains | Pandemic influenza (e.g. 2009 H1N1 swine flu) |
Antigenic variation is the main reason why:
Exam Tip: Do not confuse antigenic drift (small, gradual changes) with antigenic shift (large, sudden changes). Drift causes seasonal epidemics; shift can cause pandemics.
| Issue | Arguments for vaccination | Arguments against / concerns |
|---|---|---|
| Individual autonomy | Public health benefit outweighs individual inconvenience | Individuals should have the right to refuse medical treatment |
| Herd immunity | Protects vulnerable individuals who cannot be vaccinated | Some feel they should not be forced to take a medical intervention |
| Side effects | Serious side effects are extremely rare; benefits greatly outweigh risks | Small risk of adverse reactions (e.g. allergic reactions, very rare blood clots) |
| Cost-effectiveness | Preventing disease is far cheaper than treating it | Developing and distributing vaccines requires significant investment |
| Global equity | All populations should have equal access to vaccines | Low-income countries may lack resources for effective vaccination programmes |
| Term | Definition |
|---|---|
| Vaccine | A preparation containing antigens that stimulates active immunity without causing disease |
| Herd immunity | Indirect protection of non-immune individuals when a high proportion of the population is immune |
| Adjuvant | A substance added to a vaccine to enhance the immune response |
| Booster | An additional vaccine dose that reinforces or restores immune memory |
| Antigenic drift | Small, gradual changes in pathogen surface antigens due to mutation |
| Antigenic shift | Large, sudden changes in pathogen surface antigens due to genetic reassortment |
| R₀ (basic reproduction number) | The average number of secondary infections produced by one infected individual in a fully susceptible population |
The Edexcel 9BI0 specification places vaccination and herd immunity in Topic 6: Immunity, Infection and Forensics as the applied capstone of the immunology sequence. Lesson 7 (B and T cells) supplies the cellular substrate — vaccination works only because naive lymphocytes can be selected, expanded and parked as memory clones. Lesson 8 (antibodies and memory) supplies the molecular substrate — every vaccine aims to elicit class-switched, affinity-matured IgG plus a pre-expanded memory pool. Lesson 4 (transmission) supplies the population-level framework — the herd-immunity threshold is a direct consequence of R0. Synoptic links extend to Topic 1, where mRNA structure (5' cap, coding sequence, poly-A tail) underpins lipid-nanoparticle-delivered mRNA vaccines, and to Topic 8 (gene technology), where recombinant expression of antigenic proteins in bacterial, yeast and mammalian-cell systems makes subunit vaccines (hepatitis B HBsAg in Saccharomyces cerevisiae; HPV L1 in yeast) viable. Relevant statements concern the principle of vaccination, vaccine types, the herd-immunity threshold, eradication versus control, and the active/passive distinction (refer to the official Pearson Edexcel 9BI0 specification document for exact wording).
Question (8 marks):
A novel respiratory virus emerges with a basic reproduction number R0=5. The public health agency models a vaccination campaign using two candidate vaccines: vaccine X is a live-attenuated preparation; vaccine Y is an mRNA preparation encoding the viral surface glycoprotein.
(a) Calculate the minimum proportion of the population that must be immune to halt sustained transmission, and explain in transmission terms what the threshold represents. (3)
(b) Compare vaccines X and Y, identifying three distinct features (mechanism of antigen delivery, durability of memory, contraindications or storage requirements) that would inform the choice between them. (5)
Solution with mark scheme:
(a) M1 (AO2.1) — Substituting into the herd-immunity-threshold equation: threshold = 1−1/R0=1−1/5=0.80, so 80% of the population must be immune.
M1 (AO1.2) — At the threshold, an infected individual encounters susceptible contacts at exactly the rate needed to infect one new case on average — the effective reproduction number Reff=1. Each infection replaces itself, no more.
A1 (AO3.1a) — Below the threshold Reff<1 and the chain of transmission decays geometrically: the outbreak fades. Above the threshold Reff>1 and exponential growth resumes. The threshold is therefore a tipping point, not a guarantee of zero infections — sporadic outbreaks can still occur in unvaccinated clusters even at population-level coverage above 80%.
(b) M1 (AO1.2) — Mechanism of antigen delivery. Vaccine X (live attenuated) delivers a replication-competent but disease-incompetent virus that infects host cells, expresses native antigens and presents them on MHC class I (cell-mediated) and MHC class II (humoral after APC uptake), generating both cytotoxic T-cell and antibody responses. Vaccine Y (mRNA) delivers lipid-nanoparticle-encapsulated mRNA encoding the surface glycoprotein; host ribosomes translate the antigen, which is then displayed on MHC I from the cytosol and on MHC II after some cellular debris is taken up by APCs.
M1 (AO1.2) — Durability of memory. Live-attenuated vaccines typically generate strong, long-lasting memory in 1–2 doses (MMR confers near-lifelong protection) because antigen is presented in its native conformation and replicates in vivo, mimicking natural infection. mRNA vaccines have shown shorter durability in field data (waning antibody titres within 6–12 months for SARS-CoV-2), partly because antigen exposure ends when the mRNA is degraded.
M1 (AO2.1) — Contraindications. Vaccine X carries a small risk of reversion or of causing disease in immunocompromised individuals (HIV with low CD4 count, post-transplant immunosuppression, advanced cancer) and is contraindicated in pregnancy. Vaccine Y contains no replication-competent material and can be given safely to immunocompromised patients, though they may mount a weaker response.
M1 (AO2.1) — Storage and logistics. Vaccine X often requires standard refrigeration (2–8°C) but may be heat-sensitive; vaccine Y requires ultra-low cold-chain storage (−70°C for early Pfizer formulations; later −20°C; now refrigerator-stable for shorter periods), creating logistical barriers in low-income settings.
A1 (AO3.1a) — Synthesis. For a rapid-response campaign in a healthy adult population with cold-chain infrastructure, vaccine Y wins on speed of design (sequence to candidate in weeks) and safety profile. For long-term population control with limited cold-chain capacity, vaccine X may be preferred provided immunocompromised individuals are excluded.
Total: 8 marks.
Question (6 marks): Explain how vaccination generates protective immunity at the individual level, and how high vaccination coverage generates herd immunity at the population level. Use a named example to illustrate the herd-immunity threshold.
Mark scheme decomposition by AO:
| Marking point | AO | Credit-worthy content |
|---|---|---|
| 1 | AO1.1 | States that a vaccine introduces antigen (attenuated, inactivated, subunit, toxoid or mRNA-encoded) without causing disease, mimicking the molecular signature of the pathogen. |
| 2 | AO1.2 | Describes activation of the adaptive cascade: APC uptake and MHC II display, T-helper licensing, B-cell clonal selection and expansion, plasma-cell secretion of IgM then IgG after class switching, and parking of memory B and T cells for years. |
| 3 | AO2.1 | Explains that on field re-exposure the secondary response (1–3 day lag, IgG-dominated, high affinity from germinal-centre maturation) clears the pathogen before symptoms develop — the protective effect at the individual level. |
| 4 | AO2.1 | Defines herd immunity as indirect protection of non-immune individuals when transmission is suppressed because the pathogen runs out of susceptible hosts. States the threshold equation: threshold=1−1/R0. |
| 5 | AO3.1a | Worked example: measles has R0≈12−18, so threshold ≈92−95%. When MMR coverage falls below this in a community, sustained outbreaks reignite — observed historically in clusters with low uptake. |
| 6 | AO3.2a | Concludes that herd immunity is a threshold phenomenon, not a binary switch: below the threshold transmission grows; above it, transmission decays but is not eliminated, so unvaccinated clusters can still sustain outbreaks. Eradication (smallpox) requires sustained coverage above threshold globally; control (measles, polio) requires sustained vigilance. |
Total: 6 marks (AO1 = 2, AO2 = 2, AO3 = 2). Specimen question modelled on the Edexcel 9BI0 paper format.
Subscribe to continue reading
Get full access to this lesson and all 10 lessons in this course.